GenrAb Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $9.7M

  • Investors
  • 6

GenrAb General Information

Description

Developer of neuroprotective therapies designed to treat neurological diseases. The company utilizes advanced technology to harness the power of the human immune system, identifying fully-human monoclonal antibodies that target neurodegenerative pathways and demonstrate preclinical efficacy, enabling patients to develop treatments for slow disease progression and offer new therapeutic approaches for conditions like ALS, Parkinson's, Alzheimer's, and multiple sclerosis.

Contact Information

Website
www.genrab.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • BioLabs Pegasus Park
  • 3060 Pegasus Park Drive Building 6
  • Dallas, TX 75247
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • BioLabs Pegasus Park
  • 3060 Pegasus Park Drive Building 6
  • Dallas, TX 75247
  • United States

GenrAb Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GenrAb Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Seed Round 22-Apr-2025 $9.7M Completed Generating Revenue
2. Debt - General 01-Jan-2024 Completed Generating Revenue
1. Mezzanine 30-Dec-2022 $450K $450K Completed Generating Revenue
To view GenrAb’s complete valuation and funding history, request access »

GenrAb Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

GenrAb Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026151885-A1 Antibody constructs and conjugates for treatment of disease Pending 08-Jan-2025

GenrAb Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Actium (Dallas) Growth/Expansion Minority
Green Park & Golf Ventures Venture Capital Minority
JMS Capital Venture Capital Minority
Maytal Capital Venture Capital Minority
Research Bridge Partners Not-For-Profit Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

GenrAb FAQs

  • When was GenrAb founded?

    GenrAb was founded in 2022.

  • Where is GenrAb headquartered?

    GenrAb is headquartered in Dallas, TX.

  • What industry is GenrAb in?

    GenrAb’s primary industry is Biotechnology.

  • Is GenrAb a private or public company?

    GenrAb is a Private company.

  • What is GenrAb’s current revenue?

    The current revenue for GenrAb is .

  • How much funding has GenrAb raised over time?

    GenrAb has raised $10.2M.

  • Who are GenrAb’s investors?

    Actium (Dallas), Green Park & Golf Ventures, JMS Capital, Maytal Capital, and Research Bridge Partners are 5 of 6 investors who have invested in GenrAb.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process